USPTO serial 99554129
LONGEVIA GENOMICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- LEE, SANG MIN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with LONGEVIA GENOMICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mark A. Jansen
Mark A. Jansen Fenwick & West LLP801 California StreetMountain View, CA 94041United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment and prevention of diseases, disorders and conditions in the fields of oncology and immunology; veterinary preparations for treatment and prevention of diseases, disorders and conditions in the fields of oncology and immunology; sanitary preparations for medical purposes; diagnostic preparations for medical purposes; reagents for use in diagnostic tests for medical use; chemical diagnostic reagents for medical use; chemical preparations for testing blood for medical purposes; chemical preparations for use in DNA analysis for medical purposes; chemical reagents for medical or veterinary purposes; chemical test reagents, namely, for use in testing and evaluating DNA, genetics, and biological specimens clinical diagnostic reagents, namely, for use in testing and evaluating DNA, genetics, and biological specimens; clinical medical reagents; contrast media for use in medical imaging; diagnostic agents for medical use; diagnostic testing materials, namely, reagents and assays for testing DNA, genetics and biological specimens for medical use; genetic identity tests comprised of reagents for medical purposes; medical diagnostic test strips for testing DNA, genetics and biological specimens; indicators, namely, strips, pellets, films and liquids for medical diagnosis, namely, chemical, biological and genetic indicators for medical diagnosis | ACTIVE | — |
| 010 | Apparatus for use in medical analysis of DNA, genetics and biological specimens; apparatus for carrying-out diagnostic tests for medical purposes for testing DNA, genetics and biological specimens; diagnostic apparatus for medical purposes for testing and analyzing DNA, genetics and biological specimens; medical diagnostic instruments for detecting diseases, disorders and conditions in oncology and immunology; blood testing apparatus; medical and veterinary apparatus and instruments, namely, testing apparatus for testing DNA, genetics and biological specimens; medical apparatus for taking body fluid samples; medical apparatus for tumor diagnosis; automated medical analyzers for body fluids; medical diagnostic, examination, and monitoring equipment, namely, apparatus for DNA testing for identifying, preventing and managing diseases, disorders and conditions for medical purposes in the fields of oncology and immunology; filters for blood and blood components for medical purposes; fluid collection containers for medical use; medical instruments for extracting human body fluids; electronic analyzers for medical purposes for analyzing DNA, genetics and biological specimens; automated medical analyzers for foreign matter contained in body fluids; automatic analyzers for medical diagnosis of diseases, disorders and conditions in the fields of oncology and immunology; electromedical diagnostic instruments for testing DNA, genetics and biological specimens; genetic testing apparatus for medical purposes | ACTIVE | — |
| 042 | Scientific and technological services, namely, management and analysis, namely, genomics management and analysis of biorepository data; scientific services, namely, medical and scientific research in the field of genetics, pharmaceuticals, oncology, and immunology and research and design relating thereto; industrial analysis and research services in the fields of medicine, genetics and pharmaceuticals; development of computer hardware and software; research relating to molecular sciences; scientific analysis in the field of molecular biology; medical research; medical laboratory services; medical and pharmacological research services; scientific research for medical purposes on biorepository data in the field of genetics, pharmaceuticals, oncology and immunology; design and development of medical technology; computer programming in the medical field analysis of human tissues for medical research; biological research, clinical research on biorepository data in the field of genetics, pharmaceuticals, oncology and immunology; design and development of medical diagnostic apparatus; scientific research for medical purposes in the area of cancerous diseases; provision of information and data relating to medical and veterinary research and development; microbiological testing in the field of diseases, disorders and conditions in the fields of oncology and immunology; biotechnology testing in the field of diseases, disorders and conditions in the fields of oncology and immunology; laboratory testing in the field of diseases, disorders and conditions in the fields of oncology and immunology; scientific research and testing services in the fields of bacteriology and virology; genetic scientific research; genetic engineering services; DNA screening for scientific research purposes; medical laboratory services, namely, laboratory analysis services relating to the treatment of persons, namely, testing and analysis of biorepository data, DNA, genetics and biological specimens | ACTIVE | — |
| 044 | Medical services; genetic counseling; health screening services for diseases, disorders and conditions in the fields of oncology and immunology; providing health information; performing diagnosis of diseases; RNA or DNA services analysis for cancer diagnosis and prognosis; medical analysis services for cancer diagnosis and prognosis; genetic testing for medical purposes; medical and health care services relating to DNA, genetics and genetic testing; DNA screening for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by LonGevia Genomics Srl
- Other trademarks owned by LonGevia Genomics Srl
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named LONGEVIA GENOMICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 3, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 3, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 28, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 9, 2026 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Oct 2, 2026 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Sep 25, 2026 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Sep 18, 2026 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Sep 8, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 27, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 27, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 27, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 22, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 22, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 22, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 1, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 1, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 1, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 23, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 23, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 23, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 21, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 9, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 17, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 17, 2025 | NWAP | NEW APPLICATION ENTERED | — |